Medicus Pharma Secures $22.8M in Highly Dilutive Debt Amidst New Nasdaq Delisting Threat
MDCX sits 27% above its 52-week low of $0.25 on light trading volume (0.1× avg).
Summary
Medicus Pharma obtained $22.8 million in high-cost secured debt, providing a $17 million net cash infusion, while simultaneously receiving a second Nasdaq delisting notice for failing to meet market value requirements.
Key Events · Financing and Capital Events · MDCX
-
Secured $22.8M in High-Cost Debt
Medicus Pharma entered into a note purchase agreement for two secured promissory notes totaling $22.8 million in principal, providing a net cash infusion of $17 million after fees and repaying $2.5 million of existing debt.
-
Unfavorable Debt Terms
The financing includes an $834,225 original issue discount, an 8.75% interest rate on the A-1 Note, 5% on the B Note, and significant prepayment premiums. The debt is secured by all company and subsidiary assets, including intellectual property.
-
New Nasdaq Delisting Notice
The company received a notice from Nasdaq on May 20, 2026, for failing to meet the minimum Market Value of Listed Securities ($35 million), adding to its existing delisting threat for minimum bid price. The company has 180 days to regain compliance.
-
Continued Dilution Risk
The debt agreement explicitly permits the company to continue utilizing its existing At-The-Market (ATM) equity programs, indicating ongoing potential for shareholder dilution.
Analysis · MDCX · Life Sciences
Medicus Pharma, already facing a Nasdaq delisting for minimum bid price and operating under a going concern warning, has secured $22.8 million in new secured promissory notes. While providing a critical cash infusion of $17 million (net of fees and prior debt repayment), the terms are highly unfavorable, including significant original issue discount, high interest rates, and extensive collateralization of all company and subsidiary assets, including intellectual property. This financing is a clear sign of the company's desperate need for capital. Concurrently, the company received a second Nasdaq delisting notice for failing to meet the minimum Market Value of Listed Securities, compounding its regulatory challenges and increasing the risk of being delisted from the exchange.
At the time of this filing, MDCX was trading at $0.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.5M. The 52-week trading range was $0.25 to $7.73. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.